ID

44238

Description

A Open Label Study to Assess the Long-term Safety, Tolerability and Efficacy of Ambrisentan in Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH); ODM derived from: https://clinicaltrials.gov/show/NCT01894022

Link

https://clinicaltrials.gov/show/NCT01894022

Keywords

Versions (2)
  1. 4/15/19 4/15/19 -
  2. 9/20/21 9/20/21 -
Copyright Holder

See clinicaltrials.gov

Uploaded on

September 20, 2021

DOI

To request one please log in.

License

Creative Commons BY 4.0
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Hypertension NCT01894022

English

Eligibility Hypertension NCT01894022

1 forms  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
have been randomized to the protocol for amb115811 and have met one of the following: completed the week 16 visit in amb115811; or prematurely withdrew from amb115811 for whatever reason (where investigational product [ip] has been stopped due to safety or efficacy reasons, the subject may still enter into the open label study regardless of what treatment they are receiving [other treatments will not be supplied by the sponsor]. the investigator will decide whether or not the subject will receive the ip
Description

Study Subject Participation Status | Investigational New Drugs

Data type

boolean

Alias
UMLS CUI [1]
C2348568
UMLS CUI [2]
C0013230
subject is able and willing to give written informed consent. as part of the consent, female subjects of childbearing potential will be informed of the risk of teratogenicity and will need to be counseled in a developmentally appropriate manner on the importance of pregnancy prevention; and male subjects will need to be informed of potential risk of testicular tubular atrophy and aspermia.
Description

Informed Consent | Childbearing Potential Information Risk Teratogenesis | Childbearing Potential Information Contraceptive methods | Gender Information Risk Atrophy of testis | Gender Information Risk Aspermia

Data type

boolean

Alias
UMLS CUI [1]
C0021430
UMLS CUI [2,1]
C3831118
UMLS CUI [2,2]
C1533716
UMLS CUI [2,3]
C0035647
UMLS CUI [2,4]
C0232910
UMLS CUI [3,1]
C3831118
UMLS CUI [3,2]
C1533716
UMLS CUI [3,3]
C0700589
UMLS CUI [4,1]
C0079399
UMLS CUI [4,2]
C1533716
UMLS CUI [4,3]
C0035647
UMLS CUI [4,4]
C0156312
UMLS CUI [5,1]
C0079399
UMLS CUI [5,2]
C1533716
UMLS CUI [5,3]
C0035647
UMLS CUI [5,4]
C1704202
specific information regarding warnings, precautions, contraindications, adverse events, and other pertinent information on the gsk investigational product or other study treatment that may impact subject eligibility is provided in the investigators brochure and product label for pah indication.
Description

Information Investigational New Drugs | Information Investigational Therapy

Data type

boolean

Alias
UMLS CUI [1,1]
C1533716
UMLS CUI [1,2]
C0013230
UMLS CUI [2,1]
C1533716
UMLS CUI [2,2]
C0949266
in france, a subject will be eligible for inclusion in this study only if either affiliated to or a beneficiary of a social security category
Description

Social Security Affiliated | Social Security beneficiary

Data type

boolean

Alias
UMLS CUI [1,1]
C0037435
UMLS CUI [1,2]
C1510826
UMLS CUI [2,1]
C0037435
UMLS CUI [2,2]
C1550502
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
subject meeting any of the following criteria must not receive ambrisentan, however may still be followed-up as part of the study and be treated according to best clinical practice as decided by the investigator:
Description

ambrisentan

Data type

boolean

Alias
UMLS CUI [1]
C1176329
subject has a known hypersensitivity to the investigational products, the metabolites, or formulation excipients
Description

Hypersensitivity Investigational New Drugs | Hypersensitivity Metabolite | Hypersensitivity Formulation Excipient

Data type

boolean

Alias
UMLS CUI [1,1]
C0020517
UMLS CUI [1,2]
C0013230
UMLS CUI [2,1]
C0020517
UMLS CUI [2,2]
C0870883
UMLS CUI [3,1]
C0020517
UMLS CUI [3,2]
C0524527
UMLS CUI [3,3]
C0015237
female subjects who are pregnant or breastfeeding or no-longer agree to comply with using effective contraception as defined in the protocol.
Description

Pregnancy | Breast Feeding | Gender Contraceptive methods Refused

Data type

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0006147
UMLS CUI [3,1]
C0079399
UMLS CUI [3,2]
C0700589
UMLS CUI [3,3]
C1705116
subjects with alanine aminotransferase (alt) and/or aspartate aminotransferase (ast) >= 3x upper limit of normal (uln)
Description

Alanine aminotransferase increased | Aspartate aminotransferase increased

Data type

boolean

Alias
UMLS CUI [1]
C0151905
UMLS CUI [2]
C0151904
subjects with bilirubin >= 2xuln (>35% direct bilirubin)
Description

Elevated total bilirubin | Bilirubin, direct measurement

Data type

boolean

Alias
UMLS CUI [1]
C0741494
UMLS CUI [2]
C0201916
subjects with severe renal impairment (estimated creatinine clearance <30 millilitre per minute (ml/min) assessed within the previous 45 days) at the point of transition from study amb115811
Description

Renal Insufficiency Severe | Estimation of creatinine clearance by Cockcroft-Gault formula

Data type

boolean

Alias
UMLS CUI [1,1]
C1565489
UMLS CUI [1,2]
C0205082
UMLS CUI [2]
C2711451
subject has moderate - severe hepatic impairment (child-pugh class b-c with or without cirrhosis) at the point of transition from study amb115811
Description

Hepatic impairment Moderate Child-Pugh Classification | Hepatic impairment Severe Child-Pugh Classification | Liver Cirrhosis | Liver Cirrhosis Absent

Data type

boolean

Alias
UMLS CUI [1,1]
C0948807
UMLS CUI [1,2]
C0205081
UMLS CUI [1,3]
C4050412
UMLS CUI [2,1]
C0948807
UMLS CUI [2,2]
C0205082
UMLS CUI [2,3]
C4050412
UMLS CUI [3]
C0023890
UMLS CUI [4,1]
C0023890
UMLS CUI [4,2]
C0332197
subject with clinically significant fluid retention in the opinion of the investigator
Description

Body fluid retention

Data type

boolean

Alias
UMLS CUI [1]
C0268000
subject with clinically significant anemia in the opinion of the investigator
Description

Anemia

Data type

boolean

Alias
UMLS CUI [1]
C0002871
subjects who are to enter another clinical trial or be treated with another investigational product after exiting study amb115811.
Description

Study Subject Participation Status | Investigational New Drugs

Data type

boolean

Alias
UMLS CUI [1]
C2348568
UMLS CUI [2]
C0013230
Back to the top of the page

Similar models

Eligibility Hypertension NCT01894022

1 forms
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
Study Subject Participation Status | Investigational New Drugs
Item
have been randomized to the protocol for amb115811 and have met one of the following: completed the week 16 visit in amb115811; or prematurely withdrew from amb115811 for whatever reason (where investigational product [ip] has been stopped due to safety or efficacy reasons, the subject may still enter into the open label study regardless of what treatment they are receiving [other treatments will not be supplied by the sponsor]. the investigator will decide whether or not the subject will receive the ip
boolean
C2348568 (UMLS CUI [1])
C0013230 (UMLS CUI [2])
Informed Consent | Childbearing Potential Information Risk Teratogenesis | Childbearing Potential Information Contraceptive methods | Gender Information Risk Atrophy of testis | Gender Information Risk Aspermia
Item
subject is able and willing to give written informed consent. as part of the consent, female subjects of childbearing potential will be informed of the risk of teratogenicity and will need to be counseled in a developmentally appropriate manner on the importance of pregnancy prevention; and male subjects will need to be informed of potential risk of testicular tubular atrophy and aspermia.
boolean
C0021430 (UMLS CUI [1])
C3831118 (UMLS CUI [2,1])
C1533716 (UMLS CUI [2,2])
C0035647 (UMLS CUI [2,3])
C0232910 (UMLS CUI [2,4])
C3831118 (UMLS CUI [3,1])
C1533716 (UMLS CUI [3,2])
C0700589 (UMLS CUI [3,3])
C0079399 (UMLS CUI [4,1])
C1533716 (UMLS CUI [4,2])
C0035647 (UMLS CUI [4,3])
C0156312 (UMLS CUI [4,4])
C0079399 (UMLS CUI [5,1])
C1533716 (UMLS CUI [5,2])
C0035647 (UMLS CUI [5,3])
C1704202 (UMLS CUI [5,4])
Information Investigational New Drugs | Information Investigational Therapy
Item
specific information regarding warnings, precautions, contraindications, adverse events, and other pertinent information on the gsk investigational product or other study treatment that may impact subject eligibility is provided in the investigators brochure and product label for pah indication.
boolean
C1533716 (UMLS CUI [1,1])
C0013230 (UMLS CUI [1,2])
C1533716 (UMLS CUI [2,1])
C0949266 (UMLS CUI [2,2])
Social Security Affiliated | Social Security beneficiary
Item
in france, a subject will be eligible for inclusion in this study only if either affiliated to or a beneficiary of a social security category
boolean
C0037435 (UMLS CUI [1,1])
C1510826 (UMLS CUI [1,2])
C0037435 (UMLS CUI [2,1])
C1550502 (UMLS CUI [2,2])
Item Group
C0680251 (UMLS CUI)
ambrisentan
Item
subject meeting any of the following criteria must not receive ambrisentan, however may still be followed-up as part of the study and be treated according to best clinical practice as decided by the investigator:
boolean
C1176329 (UMLS CUI [1])
Hypersensitivity Investigational New Drugs | Hypersensitivity Metabolite | Hypersensitivity Formulation Excipient
Item
subject has a known hypersensitivity to the investigational products, the metabolites, or formulation excipients
boolean
C0020517 (UMLS CUI [1,1])
C0013230 (UMLS CUI [1,2])
C0020517 (UMLS CUI [2,1])
C0870883 (UMLS CUI [2,2])
C0020517 (UMLS CUI [3,1])
C0524527 (UMLS CUI [3,2])
C0015237 (UMLS CUI [3,3])
Pregnancy | Breast Feeding | Gender Contraceptive methods Refused
Item
female subjects who are pregnant or breastfeeding or no-longer agree to comply with using effective contraception as defined in the protocol.
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
C0079399 (UMLS CUI [3,1])
C0700589 (UMLS CUI [3,2])
C1705116 (UMLS CUI [3,3])
Alanine aminotransferase increased | Aspartate aminotransferase increased
Item
subjects with alanine aminotransferase (alt) and/or aspartate aminotransferase (ast) >= 3x upper limit of normal (uln)
boolean
C0151905 (UMLS CUI [1])
C0151904 (UMLS CUI [2])
Elevated total bilirubin | Bilirubin, direct measurement
Item
subjects with bilirubin >= 2xuln (>35% direct bilirubin)
boolean
C0741494 (UMLS CUI [1])
C0201916 (UMLS CUI [2])
Renal Insufficiency Severe | Estimation of creatinine clearance by Cockcroft-Gault formula
Item
subjects with severe renal impairment (estimated creatinine clearance <30 millilitre per minute (ml/min) assessed within the previous 45 days) at the point of transition from study amb115811
boolean
C1565489 (UMLS CUI [1,1])
C0205082 (UMLS CUI [1,2])
C2711451 (UMLS CUI [2])
Hepatic impairment Moderate Child-Pugh Classification | Hepatic impairment Severe Child-Pugh Classification | Liver Cirrhosis | Liver Cirrhosis Absent
Item
subject has moderate - severe hepatic impairment (child-pugh class b-c with or without cirrhosis) at the point of transition from study amb115811
boolean
C0948807 (UMLS CUI [1,1])
C0205081 (UMLS CUI [1,2])
C4050412 (UMLS CUI [1,3])
C0948807 (UMLS CUI [2,1])
C0205082 (UMLS CUI [2,2])
C4050412 (UMLS CUI [2,3])
C0023890 (UMLS CUI [3])
C0023890 (UMLS CUI [4,1])
C0332197 (UMLS CUI [4,2])
Body fluid retention
Item
subject with clinically significant fluid retention in the opinion of the investigator
boolean
C0268000 (UMLS CUI [1])
Anemia
Item
subject with clinically significant anemia in the opinion of the investigator
boolean
C0002871 (UMLS CUI [1])
Study Subject Participation Status | Investigational New Drugs
Item
subjects who are to enter another clinical trial or be treated with another investigational product after exiting study amb115811.
boolean
C2348568 (UMLS CUI [1])
C0013230 (UMLS CUI [2])
Back to the top of the page 

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial